Hai-Quan Mao is a Professor of Materials Science and Engineering at Johns Hopkins University, with a joint appointment in the Biomedical Engineering Department (School of Medicine). He directs the Institute for NanoBioTechnology (INBT) and leads the Translational Tissue Engineering Center. His research focuses on biomaterials, regenerative engineering, and immunoengineering, particularly developing nanomaterials for therapeutic delivery and tissue regeneration. Mao holds 35 U.S. patents, co-founded two biotech companies, and received prestigious awards including National Academy of Inventors Fellow and NSF CAREER Award. Education: BS in Chemistry (1988) and PhD in Polymer Chemistry (1993) from Wuhan University. Postdoctoral training at Johns Hopkins (1995–1998), followed by roles at Johns Hopkins Singapore (1999–2003) before joining the Whiting School faculty. Research emphasizes nanofiber scaffolds for liver/nerve regeneration, DNA/lipid nanoparticle engineering for gene therapy, and artificial lymph node matrices for immunotherapy. His lab translates biomaterials innovations into clinical applications, with NIH-funded projects addressing cancer, malaria, and tissue damage. Awards include over 60 provisional patents, multiple Johns Hopkins translational awards, and Thalheimer Awards for research. He serves as associate editor of Biomaterials and editorial board member of major journals. Lab activities include scalable nanoparticle manufacturing, machine learning for material design, and collaborations with industry/clinical partners. Recent work includes lipid nanoparticle optimization for mRNA vaccines and exosome-based therapies for Crohn’s disease.
Weiqiang Chen is a Professor of Mechanical and Biomedical Engineering at New York University's Tandon School of Engineering and Director of Research and PhD Programs. He holds a joint appointment at NYU Langone's Perlmutter Cancer Center as a Faculty Member of the Tumor Immunology Research Program. B.S. in Physics (Nanjing University, 2005) M.S. in Electrical Engineering (Shanghai Jiao Tong University, 2008) M.S. in Electrical and Computer Engineering (Purdue University, 2009) Ph.D. in Mechanical Engineering (University of Michigan, 2014) His research focuses on Lab-on-a-Chip , Organ-on-Chip systems, Biomaterials , and Mechanobiology , with applications in cancer biology, stem cell engineering, and immune monitoring. He pioneers microfabrication technologies for real-time observation of cellular interactions, including CAR T-cell immunotherapy efficacy and tumor microenvironment dynamics. Recent grants include NSF funding for leukemia bone marrow niche modeling, NIH Trailblazer Awards for glioblastoma immunotherapy research, and collaborations with the Arthritis Foundation for synovium-on-chip rheumatoid arthritis studies. His work has been supported by over $2M in federal and institutional research funding. National Science Foundation (NSF) grants for leukemia-on-chip and glioblastoma modeling National Institutes of Health (NIH) awards for immunotherapy research American Heart Association fellowships and institutional training programs Chen's scientific awards include the American Heart Association Fellow distinction, multiple Young Investigator Awards from Lab on a Chip and Biomedical Engineering Society, and recognition for his dissertation on nanotopography in stem cell differentiation. He leads the Applied Micro-Bioengineering Laboratory (AMBL) , which develops microphysiological systems for drug testing and personalized medicine. His team has created the first immunocompetent leukemia-on-a-chip for CAR T-cell therapy screening and glioblastoma models that enable patient-specific immunotherapy validation.
Professor Hala Zreiqat AM is a leading biomedical engineer at The University of Sydney , serving as the Director of the ARC Training Centre for Innovative BioEngineering . A Fellow of all major Australian academies (AAS, ATSE, FAHMS, FRSN), she develops 3D printed bioceramics for bone regeneration while championing diversity through initiatives like the IDEAL Society and BIOTech Futures mentorship program. Her work bridges academia, clinical practice, and industry in musculoskeletal research . Research Focus: Her lab creates synthetic bone scaffolds that mimic natural bone architecture, strength, and porosity, enabling non-rejected bone regeneration via patient-matched implants. Key applications include orthopaedic, dental, and maxillofacial repair , with over $18M in competitive funding and multiple patents. Current projects explore AI-driven scaffold performance prediction and anti-senescence strategies for aging-related bone loss. Scientific Trends: Recent publications highlight 3D printed nanovoxelated ceramics , antisenescence biomaterials , and multifunctional theranostic platforms . Her team integrates machine learning for scaffold design, atom probe tomography for interface analysis, and two-photon imaging for cellular monitoring in 3D environments. 2021-2022 Fulbright Senior Scholar 2018 NSW Premier's Woman of the Year 2019 Eureka Prize for Innovative Use of Technology Fellow of Australian Academy of Science (2021) Over $18M in research funding Teaching & Leadership: She designed core courses like Tissue Engineering and Nanomaterials in Medicine , mentoring 158 students in 2020 alone. As Chair of CAAR (2020-2023), she strengthens Australia-Arab collaborations. Her lab trains early-career researchers , with alumni now in academia and industry.
Sunitha Nagrath is a Professor of Chemical Engineering at the University of Michigan, leading the Nagrath Lab. Her research focuses on developing microfluidic and nanotechnology-based tools to isolate and analyze circulating tumor cells (CTCs) and extracellular vesicles (EVs) for cancer diagnostics and personalized medicine. She holds an AIMBE Fellowship and has pioneered technologies like the Graphene Oxide Chip and Microfluidic Labyrinth. Education PhD in Mechanical Engineering, Rensselaer Polytechnic Institute (2004) MS in Nuclear Engineering, Rensselaer Polytechnic Institute (2000) B.Tech in Chemical Engineering, Sri Venkateswara University (1992) Research Interests Her lab integrates engineering, biology, and clinical expertise to study CTCs' role in metastasis, develop high-throughput isolation methods, and leverage exosomes as liquid biopsy biomarkers. Key projects include: CTC-based monitoring of therapy response in lung and pancreatic cancers Microfluidic devices for simultaneous CTC and exosome analysis Functional studies of CTC-derived organoids for drug sensitivity testing Notable Achievements AIMBE Fellow (Junior Faculty, Harvard Medical School/MGH, 2008-2010) Over 150 peer-reviewed publications and patents on CTC/exosome technologies Recipient of the 2021-22 Chemical Engineering Staff Incentive Award (via lab member Mina Zeinali) Labs & Collaborations The Nagrath Lab collaborates with clinicians and engineers to translate technologies like the OncoBean Chip and EVOD chip into clinical settings. Current work emphasizes real-time CTC monitoring and exosome-based immuno-oncology strategies.
JIANG Xingyu is Chair Professor and Head of the Department of Biomedical Engineering at the Southern University of Science and Technology (SUSTech) . Since 2018 he has led a multidisciplinary team developing advanced micro- and nano-scale tools for analytical chemistry, microfluidics and nanomedicine. Education Postdoctoral Research, Harvard University (2004–2005) Ph.D. in Chemistry, Harvard University (2004) B.S. in Chemistry, University of Chicago (1999) Research Interests Professor Jiang’s research integrates analytical chemistry , microfluidics , biomedical engineering and nanomedicine . His laboratory designs microfluidic chips for point-of-care diagnostics, engineers gold nanoclusters and nanoparticles for antimicrobial and anticancer therapy, and develops soft flexible bio-electronics for neural interfaces and wearable health monitoring. Across 400+ publications, recent work demonstrates a clear trend toward translational nanomedicine : point-of-care viral variant detection, nanoantibiotic strategies against multidrug-resistant bacteria, CRISPR delivery systems for cancer therapy, and conformal electronic tattoos for human-machine interfaces. Scientific Awards & Honours Fellow, American Institute for Medical and Biological Engineering (2020) Fellow, Royal Society of Chemistry (2016) Tencent Science Exploration Award (2019) Chief Scientist, National Key R&D Program (2019–) National Science Fund for Distinguished Young Scholars (2010) Young Investigator Award, Human Frontier Science Program (2007) Research Funding & Teams He currently directs the Nanoscience Laboratory at SUSTech, hosts National Key R&D Program projects as Chief Scientist, and serves on editorial boards of Advanced Healthcare Materials , Lab on a Chip , Nanoscale Horizons , Nanoscale and Nanoscale Advances . The group is actively recruiting post-docs, research professors and technicians across chemistry, materials, biology and medical engineering disciplines.
Hsueh-Chia Chang is the Bayer Professor of Chemical Engineering in the Department of Chemical and Biomolecular Engineering at the University of Notre Dame's College of Engineering. He also holds a concurrent faculty position in the Department of Aerospace and Mechanical Engineering. As Principal Investigator of the Chang Lab, he leads cutting-edge research in microfluidic and nanofluidic technologies for biomedical applications. Prof. Chang received his B.S. in Chemical Engineering from Caltech in 1976, followed by M.S. and Ph.D. degrees in Chemical Engineering from Princeton University in 1977 and 1980, respectively. His academic journey has established him as a leader in the field of microfluidics and biosensing technologies. Chang's research focuses on developing low-cost liquid biopsy nanotechnologies for cancer screening and therapy management. His lab specializes in microfluidic and nanofluidic research coupled with electrokinetics, optics, plasmonics and acoustics for biosensing applications. Key research areas include Electrokinetics & Biosensing, Optics & Plasmonics, Nanoelectrokinetics, and Droplet Microfluidics. The Chang Lab has developed innovative platforms that can isolate and sort tumor cells, exosomes, microvesicles, lipoproteins, and stress granules from blood samples, then lyse these structures to release RNA/protein biomarkers for detection and quantification. His recent publications reveal a strong focus on extracellular vesicle diagnostics, cancer biomarker detection, and point-of-care diagnostic technologies. The research spans multiple disciplines including oncology, cardiology, and neurology, with applications for pancreatic, liver, breast, ovarian, and lung cancers as well as myocardial infarction diagnosis. Fellow of American Institute of Medical and Biological Engineering (2025) Provost Research Achievement Award, Notre Dame (2024) Fellow of the National Academy of Inventors (2020) Lifetime Achievement Award, American Electrophoresis Society (2019) Fellow of the American Physical Society (1997) Presidential Young Investigator Award, NSF (1985) Prof. Chang has advised over 50 PhD students and postdocs who have gone on to prominent positions in academia and industry. His lab has secured significant funding and has commercialized several technologies through startups like Aopia Biosciences, which launched NanoEx at ISEV 2024. The Chang Lab maintains active collaborations with medical researchers for validating their diagnostic platforms against various cancers and cardiac conditions.
Juliane Nguyen, PhD, is a Professor in the Department of Pharmacoengineering and Molecular Pharmaceutics at the UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill. She serves as Vice Chair and Director of Graduate Admissions in her department and holds an adjunct appointment as Professor of Biomedical Engineering. Dr. Nguyen is also a member of the UNC Lineberger Comprehensive Cancer Center, where she applies molecular engineering approaches to develop innovative therapeutic solutions. Dr. Nguyen's research focuses on molecular engineering to advance protein-based therapeutics, live biotherapeutics (including engineered probiotic yeast), and extracellular vesicles. Her lab develops cutting-edge technologies to treat diverse conditions including cancer, myocardial infarction, chemotherapy-induced cardiotoxicity, and inflammatory bowel diseases. Her interdisciplinary approach integrates molecular engineering, pharmaceutical sciences, and bioinformatics to create complex biologics with exceptional safety and efficacy profiles. Key research areas include developing therapeutics for cardiac repair, genetically encoded materials targeting tumor-associated macrophages, live biotherapeutics for inflammatory bowel diseases using engineered probiotic yeast, and auxetic patches for dynamic organ repair. Analysis of Dr. Nguyen's recent publications reveals a strong focus on translational research with significant contributions to cardiac repair technologies, cancer immunotherapy, inflammatory bowel disease treatments, and advanced biomaterials. Her work consistently bridges fundamental molecular engineering with clinical applications, particularly in the areas of targeted drug delivery, extracellular vesicle therapeutics, and engineered live biotherapeutics. The research demonstrates a clear trajectory toward developing clinically viable solutions for previously challenging medical conditions. Dr. Nguyen has received numerous prestigious awards and honors including the NSF CAREER Award (2018), Eshelman Innovation Award (2020), and recognition as a Fellow of the Controlled Release Society (2023). She was appointed as a Standing Member of the NIH Drug and Biologic Therapeutic Delivery Study Section (2023-2025) and serves as Executive Editor of Advanced Drug Delivery Reviews since 2021. Her Galenus Guest Professorship at ETH Zuerich (2024) and keynotes at major conferences highlight her international recognition in the field. As Director of Graduate Admissions and an active mentor, Dr. Nguyen has advised numerous PhD and Master's students who have co-authored significant publications with her. Her research is supported by competitive grants including the NSF CAREER Award and other NIH-funded projects. The Nguyen Lab maintains strong collaborations across disciplines, particularly with cardiology, oncology, and biomedical engineering researchers. She leads an interdisciplinary team focused on translating molecular engineering breakthroughs into clinically impactful therapies. The Nguyen Lab operates as a dynamic, interdisciplinary research environment combining expertise in molecular engineering, pharmaceutical sciences, and bioinformatics. The lab's mission is to revolutionize medicine by developing next-generation therapeutics that target diseases at the molecular level. Current projects focus on translating cutting-edge research into life-changing therapies for patients suffering from cancer, myocardial infarction, colitis, and other challenging conditions. The lab's innovative approach to biomolecular engineering positions it at the forefront of developing safe, effective, and personalized therapeutic solutions.
Professor Maryse Bailly is a Professor of Cell Biology at the UCL Institute of Ophthalmology, University College London, where she has been employed since December 2000, progressing from Lecturer to Reader/Associate Professor and finally to Professor in October 2020. Her research focuses on understanding fibroblast behavior in the context of ocular diseases, scarring, and fibrosis, with particular emphasis on cytoskeletal dynamics and mechanotransduction pathways. Education: Doctor of Philosophy, Universite Claude Bernard (Lyon 1), 1992 Diplome Universitaire de Technologie, Universite Claude Bernard (Lyon 1), 1983 Professor Bailly's research program investigates how fibroblasts sense and respond to mechanical and chemical stimuli in their environment, with applications to multiple ocular pathologies including trachoma, thyroid eye disease, glaucoma scarring, and myopia. Her laboratory has developed innovative in vitro and ex vivo models that allow the study of tissue contraction mechanisms within pseudo-physiological 3D environments, leading to the identification of novel therapeutic targets such as the Rac1 small GTPase and the MRTF/SRF pathway. She has established significant collaborations with clinicians at Moorfields Eye Hospital, particularly with Dr. Annegret Dahlmann-Noor on pediatric eye growth and myopia research. Analysis of Professor Bailly's publication record reveals a consistent focus on fibroblast mechanobiology with increasing emphasis on pediatric ocular development in recent years. Her work bridges fundamental cell biology with translational applications, particularly in understanding the biomechanical properties of fibroblasts in myopia development and post-surgical scarring. The research demonstrates strong interdisciplinary connections between ophthalmology, cell biology, and tissue engineering. Teaching: CELL0016 - Actin cytoskeleton and Intermediate Filaments CELL0017 - Fibrosis and mechanotransduction CELL0009 - Models organisms and techniques MECH0031 MSc Biomaterials & Tissue Engineering - Modeling tissue contraction and fibrosis
Dist. Professor Leslie Yeo is a distinguished faculty member at RMIT University's School of Engineering, where he leads the Micro/Nanophysics Research Laboratory (MNRL). With a PhD from Imperial College London (2002), he has held positions at Monash University and the University of Notre Dame before joining RMIT. His research focuses on the interactions between high-frequency sound waves and matter at micro and nanoscales. Leslie Yeo's educational background includes a PhD from Imperial College London (2002), where he received the Dudley Newitt prize for outstanding computational/theoretical work. Prior to his academic career, he worked as a Mathematical Modeller at Det Norske Veritas UK. He held prestigious Australian Research Fellowships (2009-2017) that supported his groundbreaking work in micro and nanophysics. Professor Yeo's research interests center around high-frequency (MHz order) sound waves interacting with various materials including fluids, two-dimensional and bulk crystals, biomolecules, cells and microorganisms. His work explores both fundamental physicochemical phenomena and practical applications in microfluidics, drug delivery, diagnostics, tissue engineering, and materials synthesis. His research has significant implications for health technologies, environmental applications, and sustainable energy solutions, aligning with UN Sustainable Development Goals 3 (Good Health and Well-Being) and 7 (Affordable and Clean Energy). Analysis of Professor Yeo's recent publications reveals a strong focus on acoustofluidics and its diverse applications. His work demonstrates expertise in using surface acoustic waves for bacterial inactivation, synthesis of metal-organic frameworks, cell membrane manipulation, and energy conversion technologies. The research spans multiple disciplines including biomedical engineering, materials science, and environmental technology, with particular emphasis on practical applications that address real-world challenges. 2023: Fellowship of the Institution of Engineering & Technology (FIET) 2021: RMIT University Science, Technology, Engineering & Medicine College Research Impact Award 2019: RMIT University Distinguished Professorship 2018: RMIT University Vice-Chancellor's Award for Research Excellence 2016: Johnson & Johnson World Without Disease Quickfire Challenge Award 2007: Young Tall Poppy Science Award Professor Yeo has supervised numerous research students across engineering and science disciplines, with current projects focusing on acoustomicrofluidic synthesis of nanomaterials, high-frequency mechanobiology applications, and diagnostic technologies. His editorial roles include Editor-in-Chief of the American Institute of Physics journal Biomicrofluidics and Associate Editor of Frontiers in Bioengineering & Biotechnology. His work has been widely featured in media outlets including ABC's Catalyst, The Economist, and Nature. The Micro/Nanophysics Research Laboratory under Professor Yeo's leadership is at the forefront of fundamental and applied research on nonlinear high-frequency electroacoustic interactions. The laboratory has discovered novel physicochemical phenomena and actively develops theories to explain the fundamental mechanisms behind these discoveries, with applications ranging from medical diagnostics to sustainable energy solutions.
Anna Salvati is an Associate Professor specializing in nanomedicine and drug delivery systems. Her research focuses on nanoparticle-cell interactions, biomolecular corona formation, and the physicochemical properties governing nanomaterial behavior in biological environments. Key research themes include cellular uptake mechanisms, toxicity of nanomaterials, and nanoparticle targeting strategies. Recent publications highlight her work on nanoparticle stability, membrane interactions, and environmental impacts of microplastics. Her studies integrate multiomics approaches, advanced imaging, and interlaboratory validation to address challenges in nanomedicine design and safety testing. Current projects explore the role of high-density lipoproteins in nanoparticle functionality and the modulation of drug release kinetics through material engineering.
Pengyu Chen is Francis Family Associate Professor and Ginn Faculty Achievement Fellow in Materials Engineering at Auburn University. His NIH-funded research develops nanoplasmonic biosensors for rapid disease diagnosis and immune monitoring, with applications in precision medicine and cancer immunotherapy. Research focuses on: Rapid diagnostic technologies for COVID-19 and other diseases Single-cell analysis platforms Nanoparticle-based cancer therapies Food/environmental safety monitoring Recent publications demonstrate innovations in nanoplasmonic sensing, targeted drug delivery, 3D-printed implants, and tumor microenvironment analysis. His work integrates nanotechnology, immunology, and microfluidics for biomedical applications.
Dr Amin Ardestani , Senior Lecturer in Metabolic Signaling at the Biomedical Institute for Multimorbidity (BIM), Hull York Medical School (HYMS) , specializes in unraveling molecular mechanisms of pancreatic β-cell failure in diabetes. His research program identifies novel therapeutic targets through signal transduction studies in metabolic disorders. Bachelor's in Biology, Tarbiat Moalem University (2004) Master's in Biochemistry, Institute of Biochemistry and Biophysics (2007) PhD in Biology, University of Bremen (2013) Junior Group Leader at University of Bremen (2014-2023) Research focuses on Hippo and mTOR signaling pathways in β-cell biology, autoimmunity, and regeneration. His work bridges mechanistic biology with drug discovery for diabetes, with significant findings on PHLPP1/2 phosphatases and MST1/2 kinases. Recent publications highlight therapeutic strategies for β-cell protection , including small molecule inhibitors (e.g., MST1/2 inhibitors) and metabolic enzyme modulation (LDHA). Collaborative studies explore SARS-CoV-2 interactions with pancreatic cells and cross-talk between acinar and β-cells in diabetes. 2019 JDRF Advanced Postdoctoral Fellowship 2018 Impulse grant & Career Advancement Award 2017 Early Investigators awards (Endocrine Society, EFSD/Lilly Programme) 2014 Albert Renold Fellowship & Bremer Studienpreis Professional roles include Editorial Board Member at Scientific Reports and Associate Editor at Frontiers in Endocrinology . He reviews grants for DFG, Diabetes UK, and ISF, and evaluates manuscripts for top-tier journals like Cell Metabolism and Nature Communications.
Carlos Salomon Gallo is a Professor and NHMRC Investigator Fellow (EL2) at The University of Queensland's Centre for Clinical Research, affiliated with the School of Biomedical Sciences. He directs the Centre for Extracellular Vesicle Nanomedicine and leads the Exosome Biology Laboratory. A globally recognized key opinion leader in extracellular vesicles (ranked 3rd worldwide by Expertscape), his research focuses on EV biology for diagnostic and therapeutic applications in ovarian cancer, gestational diabetes, preeclampsia, and other obstetrical syndromes. His research integrates proteomics (SWATH-MS), miRNA analysis, and advanced isolation techniques to develop liquid biopsies. Core interests include: EV biomarker discovery and validation for early disease detection. Mechanisms of EV-mediated signaling in metabolic and oncological pathologies. Engineering EVs for targeted drug delivery and CRISPR-Cas therapeutics. Clinical translation of EV-based diagnostics (IVDs) and therapeutics. Analysis of his recent articles reveals a dominant focus on EV profiling in pregnancy complications (gestational diabetes, preeclampsia) and oncology (ovarian cancer), utilizing multi-omics approaches. Key trends include developing high-sensitivity EV biosensors, understanding hypoxia-induced EV signaling, and exploring 3D models for EV research. He has received significant recognition, including: NHMRC Emerging Leadership Fellow NHMRC Investigator Fellow (EL2) He leads the Exosome Biology Laboratory and the UQ Centre for Extracellular Vesicle Nanomedicine, fostering cross-disciplinary collaboration. His work involves extensive national and international partnerships, evidenced by leadership roles in the Centre for Clinical Diagnostics and over 20 invited international talks in 5 years. He actively mentors HDR students and contributes to global EV research standards (MISEV2023).
Quan Liu, M.D., Ph.D., is an Associate Professor at the School of Medicine, Southern University of Science and Technology (SUSTech), where he has been employed since August 2018. He also serves as Deputy Secretary of the Joint Party Committee of the School of Medicine, Chairman of the Joint Labor Union of the School of Medicine, and Vice Chairman of the Transplant Immunology Professional Committee of the Immunotherapy Engineering Branch of the Chinese Society of Biomedical Engineering. Additionally, he holds the position of Associate Chief Physician at the Second Affiliated Hospital of Harbin Medical University. Dr. Liu received his Medical Degree (M.D.) from Harbin Medical University in 2002, followed by surgical training at the Second Affiliated Hospital of Harbin Medical University from 2002 to 2008, specializing in cardiothoracic surgery. He pursued his Ph.D. at the University of Pittsburgh, where he spent over 8 years (2009-2017) at the Thomas E. Starzl Transplantation Institute studying transplantation immunobiology, inflammation regulation, and immunobiology of IL-33 and regulatory T cells (Treg) with Drs. Heth Turnquist and Adrian Morelli. Dr. Liu's research focuses on three primary areas: (1) Alloantigen presentation in transplantation, (2) Immunobiology of IL-33, Treg and ILC2 in settings of transplantation, inflammation regulation and tumor, and (3) Immunotherapy. His work has made significant contributions to the field of transplant immunology, particularly in elucidating the role of donor dendritic cell-derived exosomes in mediating the semi-direct pathway of alloantigen presentation, revealing the role of intra-allograft recipient-derived dendritic cells in maintaining transplant rejection, and investigating the role of IL-33 in tissue protection during acute lung injury and heart transplant rejection. His research findings have been included in the classic immunology textbook Janeway's Immunobiology (10th Ed, 2022). Dr. Liu's publications demonstrate a strong focus on immunology, particularly transplant immunology, with recurring themes of IL-33, regulatory T cells, and mechanisms of immune regulation in transplantation settings. His work spans from basic immunological mechanisms to potential clinical applications in transplantation and cancer. Provincial Science and Technology Progress Second Prize (2007) Provincial Science and Technology Progress Second Prize (2008) Young Scientist Award at the American Transplant Congress (2013) Distinguished Young Talents project of the Second Affiliated Hospital of Harbin Medical University (2017) Dr. Liu has successfully completed a National Natural Science Foundation of China Youth Fund project and is currently leading a National Natural Science Foundation of China General Project (2020-2023). He has supervised doctoral students and has been actively involved in teaching undergraduate courses in Biochemistry, Physiology, and Pathophysiology, as well as graduate courses in Immunology. His laboratory at SUSTech has developed advanced research capabilities including over 30 mouse strains (more than 10 developed independently), access to a Seahorse XFe96 cell energy metabolism analyzer, and a CyTOF Helios mass cytometer for advanced immunological studies. Dr. Liu leads a research group at SUSTech focused on tumor immunity and immunotherapy, neuro-immune-metabolic interactions, and transplant immunity. The laboratory has established significant experimental capabilities including over 30 mouse strains (more than 10 developed independently), access to a Seahorse XFe96 cell energy metabolism analyzer for immunometabolism research, and a CyTOF Helios mass cytometer for advanced immunological studies.
Dr. Premdass Ramdas is a Senior Lecturer at Monash University Malaysia, affiliated with the Jeffrey Cheah School of Medicine and Health Sciences. He joined in October 2023 with over 13 years of experience in medical biotechnology and health sciences, focusing on cancer research and bioactive natural compounds. PhD in Cancer Proteomics and Genomics, University of Malaya MSc in Medical Sciences (Cancer Genomics and Natural Products), International Medical University BSc with First-Class Honors His research focuses on the anticancer mechanisms of tocotrienols, utilizing proteomics, genomics, bioinformatics, and mouse models. He explores epigenetics, nutrigenomics, RNA/microRNA analysis, exosome biology, and AI-driven big data in cancer. His work contributes to UN Sustainable Development Goals in health and well-being. Recent publications show a strong trend in systematic reviews and mechanistic studies on vitamin E analogues in cancer, particularly colorectal and breast cancers. His research integrates molecular biology with computational approaches, including molecular docking and data mining. First-class honors for BSc Malaysian Palm Oil Board Scholarship for MSc MyBrain15 Scholarship for PhD Dr. Ramdas has secured research grants such as FRGS and actively supervises research projects. He is currently accepting PhD students and has co-supervised non-HDR reviews, indicating active mentorship. He has no known labs or teams explicitly mentioned, but collaborates extensively, particularly with Prof. Radhakrishnan A.K.
